Lenalidomide in follicular lymphoma
Christopher R. Flowers, John P. Leonard, Nathan Fowler
Abstract
Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.
Topics & Concepts
LenalidomideFollicular lymphomaMedicineThalidomideInternal medicineLymphomaOncologyMultiple myelomaLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCNS Lymphoma Diagnosis and Treatment